Market Overview

Global Kidney Cancer Therapeutics & Diagnostics Market (2018-2023): Rising Number of Kidney Cancer Cases is Driving Growth -


The "Global
Kidney Cancer Therapeutics & Diagnostics Market - Segmented by Cancer
Type, Therapy, Diagnostics, End-users, and Geography - Growth, Trends,
and Forecast (2018 - 2023)"
report has been added to's

The market for the period 2018-2023 is expected to register a CAGR of

The growth of the market is mainly driven by factors, such as rising
aging population, changes in lifestyle, such as increased intake of
alcohol and disproportionate smoking, and government policies to provide
better care for Kidney Cancer.

Rising Number of Kidney Cancer Cases

The need for early identification of these diseases will lead to the
growth in the market for kidney cancer therapeutics and diagnostics.
Increasing detection of presymptomatic tumors by imaging procedures,
such as ultrasonography, computed tomography, and magnetic resonance
imaging, does not fully explain the upward incidence trends of renal
cell carcinoma.

Other factors, such as increased R&D expenditure of pharmaceutical
companies and increasing incidences of chronic diseases and aging
population will lead to the growth of the market in the forecast period.

Key Highlights

  • High Cost Associated With Treatment
  • North America to Dominate Market

Notable Developments

  • The U.S. Food and Drug Administration today approved Sutent (sunitinib
    malate) for the adjuvant treatment of adult patients who are at high
    risk of kidney cancer (renal cell carcinoma) returning after a kidney
    has been removed (nephrectomy).

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

7. Market Segmentation

8. Competitive Landscape

9. Key Players

  • Bayer
  • F. Hoffmann-La Roche
  • Glaxosmithkline
  • Novartis
  • Pfizer
  • Abbott Laboratories
  • Amgen
  • Genentech
  • Cerulean Pharma
  • Seattle Genetics

10. Future of the Market

For more information about this report visit

View Comments and Join the Discussion!